Patents by Inventor Abraham Bout

Abraham Bout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10934571
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: March 2, 2021
    Assignee: Merus N.V.
    Inventors: Patricius Hendrikus Van Berkel, Ronald Hendrik Brus, Abraham Bout, Ton Logtenberg
  • Patent number: 10562956
    Abstract: The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: February 18, 2020
    Assignee: Mallinckrodt Pharma IP Trading D.A.C.
    Inventors: Abraham Bout, Joseph Grimbergen, Jacob Koopman
  • Patent number: 10004787
    Abstract: The present invention relates to fibrinogen preparations enriched in ?-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of ?-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by ?-extended fibrinogen are improved. In addition, plasmin-mediated degradation of ?-extended fibrinogen is reduced as compared to plasma derived fibrinogen.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: June 26, 2018
    Assignee: Mallinckrodt Pharma IP Trading D.A.C.
    Inventors: Joseph Grimbergen, Jacob Koopman, Abraham Bout
  • Publication number: 20180112247
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Application
    Filed: December 27, 2017
    Publication date: April 26, 2018
    Applicant: Merus N.V.
    Inventors: Patricius Hendrikus VAN BERKEL, Ronald Hendrik BRUS, Abraham BOUT, Ton LOGTENBERG
  • Publication number: 20180094289
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Applicant: Merus N.V.
    Inventors: Patricius Hendrikus VAN BERKEL, Ronald Hendrik BRUS, Abraham BOUT, Ton LOGTENBERG
  • Publication number: 20170266262
    Abstract: The present invention relates to fibrinogen preparations enriched in ?-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of ?-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by ?-extended fibrinogen are improved. In addition, plasmin-mediated degradation of ?-extended fibrinogen is reduced as compared to plasma derived fibrinogen.
    Type: Application
    Filed: June 5, 2017
    Publication date: September 21, 2017
    Inventors: Joseph Grimbergen, Jacob Koopman, Abraham Bout
  • Patent number: 9694054
    Abstract: The present invention relates to fibrinogen preparations enriched in ?-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of ?-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by ?-extended fibrinogen are improved. In addition, plasmin-mediated degradation of ?-extended fibrinogen is reduced as compared to plasma derived fibrinogen.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: July 4, 2017
    Assignee: Mallinckrodt Oharma IP Trading D.A.C.
    Inventors: Joseph Grimbergen, Jacob Koopman, Abraham Bout
  • Publication number: 20170037108
    Abstract: The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 9, 2017
    Inventors: Abraham Bout, Joseph Grimbergen, Jacob Koopman
  • Publication number: 20160319320
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Application
    Filed: April 4, 2016
    Publication date: November 3, 2016
    Applicant: Merus N.V.
    Inventors: Patricius Hendrikus Van Berkel, Ronald Hendrik Brus, Abraham Bout, Ton Logtenberg
  • Publication number: 20160158323
    Abstract: The present invention relates to fibrinogen preparations enriched in ?-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of ?-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by ?-extended fibrinogen are improved. In addition, plasmin-mediated degradation of ?-extended fibrinogen is reduced as compared to plasma derived fibrinogen.
    Type: Application
    Filed: October 7, 2015
    Publication date: June 9, 2016
    Inventors: Joseph Grimbergen, Jacob Koopman, Abraham Bout
  • Patent number: 9303081
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: April 5, 2016
    Assignee: Merus B.V.
    Inventors: Patricius H. C. Van Berkel, Ronald Hendrik Brus, Ton Logtenberg, Abraham Bout
  • Publication number: 20130243773
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 19, 2013
    Applicant: Merus B.V.
    Inventors: Patricius Hendrikus Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
  • Publication number: 20130011382
    Abstract: The present invention relates to fibrinogen preparations enriched in ?-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of ?-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by ?-extended fibrinogen are improved. In addition, plasmin-mediated degradation of ?-extended fibrinogen is reduced as compared to plasma derived fibrinogen.
    Type: Application
    Filed: January 7, 2011
    Publication date: January 10, 2013
    Applicant: PROFIBRIX BV
    Inventors: Joseph Grimbergen, Jacob Koopman, Abraham Bout
  • Patent number: 8236293
    Abstract: Cells capable of at least, in part, complementing adenovirus an adenovirus defective in E2A function. Such cells include a nucleic acid-encoding adenovirus E2A or a functional part, derivative, temperature-sensitive mutation and/or analogue thereof, integrated into the cell's genome. Methods for producing an adenovirus particle/vector with a functional deletion of E2A are also disclosed. Such methods involve providing a cell with the functionally deleted adenovirus vector, culturing the cell, and harvesting viral particles. The functional deletion may comprise a deletion in E2A. The nucleic acid-encoding E2A in the cell's genome may lack sequence overlap with the vector, preventing formation of a replication-competent adenovirus or restoration of E2A function. The adenovirus vector may further include a functional deletion in the E1-region.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: August 7, 2012
    Assignee: Crucell Holland B.V.
    Inventors: Frits J. Fallaux, Robert C. Hoeben, Abraham Bout, Domenico Valerio, Alex J. van der Eb, Govert Schoutten
  • Patent number: 8236561
    Abstract: The invention provides an immortalized human retina cell expressing E1A and E1B proteins of an adenovirus, wherein the cell has recombinant nucleic acid encoding an IgA molecule in expressible format. Also provided is a method for recombinant production of an IgA molecule, the method involving culturing a cell of the invention and expressing the recombinant nucleic acid encoding an IgA.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: August 7, 2012
    Assignee: Crucell Holland B.V.
    Inventors: David H. A. Jones, Abraham Bout
  • Patent number: 8221971
    Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: July 17, 2012
    Assignee: Crucell Holland B.V.
    Inventors: Abraham Bout, Menzo Jans Emco Havenga, Ronald Vogels
  • Publication number: 20110177073
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Application
    Filed: March 4, 2011
    Publication date: July 21, 2011
    Inventors: Patrick H. C. Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
  • Publication number: 20110177524
    Abstract: The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.
    Type: Application
    Filed: July 9, 2009
    Publication date: July 21, 2011
    Applicant: PROFIBRIX BV
    Inventors: Abraham Bout, Joseph Maria Grimberger, Jacob Laurens Koopman
  • Patent number: 7968087
    Abstract: A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fragments from at least two different viruses, such as two different adenoviruses, including adenovirus of subgroup C or subgroup B (for example, adenovirus 16). The protein fragments can comprise a tissue tropism-determining fragment of a fiber protein derived from a subgroup B adenovirus. Also, cells for producing such gene delivery vehicles and pharmaceutical compositions containing these gene delivery vehicles are provided.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: June 28, 2011
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Menzo J. E. Havenga, Abraham Bout
  • Patent number: RE47770
    Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: December 17, 2019
    Assignee: Merus N.V.
    Inventors: Patricius H. C. Van Berkel, Ronald Hendrik Brus, Ton Logtenberg, Abraham Bout